ID   FADS3_RAT               Reviewed;         449 AA.
AC   Q8K1P9;
DT   02-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   27-MAR-2024, entry version 126.
DE   RecName: Full=Fatty acid desaturase 3 {ECO:0000303|PubMed:19752397};
DE            EC=1.14.19.- {ECO:0000269|PubMed:24070791};
DE   AltName: Full=Delta(13) fatty acid desaturase {ECO:0000305|PubMed:24070791};
DE            Short=Delta(13) desaturase {ECO:0000305|PubMed:24070791};
DE   AltName: Full=trans-vaccenate Delta13-desaturase;
GN   Name=Fads3 {ECO:0000303|PubMed:19752397, ECO:0000303|PubMed:24070791};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RA   D'Andrea S., Guillou H., Jan S., Daval S., Rioux V., Legrand P.;
RT   "Characterization of a novel putative fatty acid desaturase from rat.";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   TISSUE SPECIFICITY.
RX   PubMed=19752397; DOI=10.1194/jlr.m000588;
RA   Pedrono F., Blanchard H., Kloareg M., D'andrea S., Daval S., Rioux V.,
RA   Legrand P.;
RT   "The fatty acid desaturase 3 gene encodes for different FADS3 protein
RT   isoforms in mammalian tissues.";
RL   J. Lipid Res. 51:472-479(2010).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=24070791; DOI=10.1194/jlr.m042572;
RA   Rioux V., Pedrono F., Blanchard H., Duby C., Boulier-Monthean N.,
RA   Bernard L., Beauchamp E., Catheline D., Legrand P.;
RT   "Trans-vaccenate is Delta13-desaturated by FADS3 in rodents.";
RL   J. Lipid Res. 54:3438-3452(2013).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.
RX   PubMed=30262139; DOI=10.1016/j.bbrc.2018.09.132;
RA   Garcia C., Guillocheau E., Richard L., Drouin G., Catheline D., Legrand P.,
RA   Rioux V.;
RT   "Conversion of dietary trans-vaccenic acid to trans11,cis13-conjugated
RT   linoleic acid in the rat lactating mammary gland by Fatty Acid Desaturase
RT   3-catalyzed methyl-end Delta13-desaturation.";
RL   Biochem. Biophys. Res. Commun. 505:385-391(2018).
CC   -!- FUNCTION: Mammals have different sphingoid bases that differ in their
CC       length and/or pattern of desaturation and hydroxyl groups. The
CC       predominant sphingoid base that comprises mammalian ceramides is
CC       sphing-4-enine (sphingosine or SPH) which has a trans (E) desaturation
CC       at carbon 4. FADS3 is a desaturase that introduces a cis (Z) double
CC       bond between carbon 14 and carbon 15 of the sphingoid base (also known
CC       as long chain base, LCB), producing LCBs such as sphinga-4,14-dienine
CC       (SPD, d18:2(4E,14Z)) from SPH. Prefers SPH-containing ceramides (N-
CC       acylsphing-4-enines) as substrates. Capable of metabolizing also the
CC       SPH in its free form. SPD ceramides occur widely in mammalian tissues
CC       and cells. Due to their unusual structure containing a cis double bond,
CC       SPD ceramides may have an opposite, negative role in lipid microdomain
CC       formation relative to conventional ceramides. Could be involved in the
CC       detoxification of 1-deoxy sphingolipids, by desaturating the cytotoxic
CC       1-deoxysphinganine (1-deoxySA, m18:0), produced under pathological
CC       conditions, to 1-deoxysphingenine (1-deoxysphingosine, 1-deoxySO,
CC       m18:1). Although prefers SPH-containing ceramides (N-acylsphing-4-
CC       enines) as substrates, it also exhibits activity toward
CC       dihydrosphingosine-containing CERs (N-acylsphinganines) and produces
CC       14Z-SPH-containing sphingolipids. Its desaturase mechanism involves an
CC       electron transfer facilitated by cytochrome b5 (By similarity). FADS3
CC       also acts as a methyl-end fatty acyl coenzyme A (CoA) desaturase that
CC       introduces a cis double bond between the preexisting double bond and
CC       the terminal methyl group of the fatty acyl chain. Desaturates (11E)-
CC       octadecenoate (trans-vaccenoate, the predominant trans fatty acid in
CC       human milk) at carbon 13 to generate (11E,13Z)-octadecadienoate (also
CC       known as conjugated linoleic acid 11E,13Z-CLA) (PubMed:24070791,
CC       PubMed:30262139). {ECO:0000250|UniProtKB:Q9Y5Q0,
CC       ECO:0000269|PubMed:24070791, ECO:0000269|PubMed:30262139}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphing-4-enine + 2 Fe(II)-[cytochrome b5] + 2 H(+) +
CC         O2 = an N-acyl-sphinga-4E,14Z-dienine + 2 Fe(III)-[cytochrome b5] + 2
CC         H2O; Xref=Rhea:RHEA:63928, Rhea:RHEA-COMP:10438, Rhea:RHEA-
CC         COMP:10439, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:29033, ChEBI:CHEBI:29034, ChEBI:CHEBI:52639,
CC         ChEBI:CHEBI:139573; Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63929;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 Fe(II)-[cytochrome b5] + 2 H(+) + N-(hexanoyl)sphing-4-enine
CC         + O2 = 2 Fe(III)-[cytochrome b5] + 2 H2O + N-hexanoyl-sphinga-4E,14Z-
CC         dienine; Xref=Rhea:RHEA:63940, Rhea:RHEA-COMP:10438, Rhea:RHEA-
CC         COMP:10439, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:29033, ChEBI:CHEBI:29034, ChEBI:CHEBI:63867,
CC         ChEBI:CHEBI:149631; Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63941;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 Fe(II)-[cytochrome b5] + 2 H(+) + O2 + sphing-4-enine = 2
CC         Fe(III)-[cytochrome b5] + 2 H2O + sphinga-4E,14Z-dienine;
CC         Xref=Rhea:RHEA:76483, Rhea:RHEA-COMP:10438, Rhea:RHEA-COMP:10439,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:29033, ChEBI:CHEBI:29034, ChEBI:CHEBI:57756,
CC         ChEBI:CHEBI:83568; Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:76484;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(11E)-octadecenoyl-CoA + 2 Fe(II)-[cytochrome b5] + 2 H(+) +
CC         O2 = (11E,13Z)-octadecadienoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2
CC         H2O; Xref=Rhea:RHEA:46056, Rhea:RHEA-COMP:10438, Rhea:RHEA-
CC         COMP:10439, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:29033, ChEBI:CHEBI:29034, ChEBI:CHEBI:74296,
CC         ChEBI:CHEBI:85650; Evidence={ECO:0000269|PubMed:24070791,
CC         ECO:0000269|PubMed:30262139};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46057;
CC         Evidence={ECO:0000269|PubMed:24070791, ECO:0000305|PubMed:30262139};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 Fe(II)-[cytochrome b5] + 2 H(+) + N-acyl-1-deoxysphinganine
CC         + O2 = 2 Fe(III)-[cytochrome b5] + 2 H2O + N-acyl-1-deoxysphing-14Z-
CC         enine; Xref=Rhea:RHEA:76487, Rhea:RHEA-COMP:10438, Rhea:RHEA-
CC         COMP:10439, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:29033, ChEBI:CHEBI:29034, ChEBI:CHEBI:67111,
CC         ChEBI:CHEBI:195246; Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:76488;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphinganine + 2 Fe(II)-[cytochrome b5] + 2 H(+) + O2
CC         = an N-acylsphing-14Z-enine + 2 Fe(III)-[cytochrome b5] + 2 H2O;
CC         Xref=Rhea:RHEA:76563, Rhea:RHEA-COMP:10438, Rhea:RHEA-COMP:10439,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:29033, ChEBI:CHEBI:29034, ChEBI:CHEBI:31488,
CC         ChEBI:CHEBI:195278; Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:76564;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y5Q0};
CC   -!- PATHWAY: Lipid metabolism; polyunsaturated fatty acid biosynthesis.
CC       {ECO:0000305|PubMed:24070791}.
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000250|UniProtKB:Q9Y5Q0}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q9Y5Q0}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Essentially expressed in liver and kidney and to a
CC       lesser extent in heart, adipose tissue, stomach and pancreas (at
CC       protein level) (PubMed:19752397). Higher expression in lactating
CC       mammary gland than in liver (PubMed:30262139).
CC       {ECO:0000269|PubMed:19752397, ECO:0000269|PubMed:30262139}.
CC   -!- DOMAIN: The protein sequence includes a number of characteristic
CC       features of microsomal fatty acid desaturases including the three
CC       histidine boxes (these domains may contain the active site and/or be
CC       involved in metal ion binding), and the N-terminal cytochrome b5 domain
CC       containing the heme-binding motif, HPGG, similar to that of other fatty
CC       acid desaturases. {ECO:0000250|UniProtKB:Q9Y5Q0}.
CC   -!- MISCELLANEOUS: Two potential isoforms are detected in various tissues.
CC       A 75 kDa isoform is expressed in lung, spleen and thymus. A 37 kDa
CC       isoform is highly expressed in skeletal and abdominal muscles, brain
CC       and ovary and to a lesser extent in heart, lung, brown adipose tissue
CC       and eye. {ECO:0000269|PubMed:19752397}.
CC   -!- SIMILARITY: Belongs to the fatty acid desaturase type 1 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ494720; CAD38527.1; -; mRNA.
DR   RefSeq; NP_775160.1; NM_173137.1.
DR   AlphaFoldDB; Q8K1P9; -.
DR   SMR; Q8K1P9; -.
DR   STRING; 10116.ENSRNOP00000027693; -.
DR   SwissLipids; SLP:000001192; -.
DR   PhosphoSitePlus; Q8K1P9; -.
DR   PaxDb; 10116-ENSRNOP00000027693; -.
DR   Ensembl; ENSRNOT00000100217.1; ENSRNOP00000090422.1; ENSRNOG00000020385.4.
DR   Ensembl; ENSRNOT00055030332; ENSRNOP00055024392; ENSRNOG00055017907.
DR   Ensembl; ENSRNOT00060053120; ENSRNOP00060044169; ENSRNOG00060030542.
DR   Ensembl; ENSRNOT00065058332; ENSRNOP00065048008; ENSRNOG00065033958.
DR   GeneID; 286922; -.
DR   KEGG; rno:286922; -.
DR   UCSC; RGD:628876; rat.
DR   AGR; RGD:628876; -.
DR   CTD; 3995; -.
DR   RGD; 628876; Fads3.
DR   eggNOG; KOG4232; Eukaryota.
DR   GeneTree; ENSGT00950000182990; -.
DR   HOGENOM; CLU_016265_0_1_1; -.
DR   InParanoid; Q8K1P9; -.
DR   OMA; FGGMQYQ; -.
DR   OrthoDB; 294339at2759; -.
DR   PhylomeDB; Q8K1P9; -.
DR   TreeFam; TF313604; -.
DR   UniPathway; UPA00222; -.
DR   UniPathway; UPA00658; -.
DR   PRO; PR:Q8K1P9; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000020385; Expressed in lung and 18 other cell types or tissues.
DR   ExpressionAtlas; Q8K1P9; baseline and differential.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016717; F:oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water; IBA:GO_Central.
DR   GO; GO:0006629; P:lipid metabolic process; IBA:GO_Central.
DR   GO; GO:0006665; P:sphingolipid metabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006636; P:unsaturated fatty acid biosynthetic process; IEA:UniProtKB-UniPathway.
DR   CDD; cd03506; Delta6-FADS-like; 1.
DR   Gene3D; 3.10.120.10; Cytochrome b5-like heme/steroid binding domain; 1.
DR   InterPro; IPR001199; Cyt_B5-like_heme/steroid-bd.
DR   InterPro; IPR036400; Cyt_B5-like_heme/steroid_sf.
DR   InterPro; IPR005804; FA_desaturase_dom.
DR   InterPro; IPR012171; Fatty_acid_desaturase.
DR   PANTHER; PTHR19353; FATTY ACID DESATURASE 2; 1.
DR   PANTHER; PTHR19353:SF11; FATTY ACID DESATURASE 3; 1.
DR   Pfam; PF00173; Cyt-b5; 1.
DR   Pfam; PF00487; FA_desaturase; 1.
DR   PIRSF; PIRSF015921; FA_sphinglp_des; 1.
DR   PRINTS; PR00363; CYTOCHROMEB5.
DR   SMART; SM01117; Cyt-b5; 1.
DR   SUPFAM; SSF55856; Cytochrome b5-like heme/steroid binding domain; 1.
DR   PROSITE; PS50255; CYTOCHROME_B5_2; 1.
PE   1: Evidence at protein level;
KW   Electron transport; Endoplasmic reticulum; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism; Membrane;
KW   Oxidoreductase; Reference proteome; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..449
FT                   /note="Fatty acid desaturase 3"
FT                   /id="PRO_0000307110"
FT   TOPO_DOM        1..137
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        138..158
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        159..163
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        164..184
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        185..268
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        269..289
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        290..310
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        311..331
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        332..449
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          24..101
FT                   /note="Cytochrome b5 heme-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00279"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           186..190
FT                   /note="Histidine box-1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5Q0"
FT   MOTIF           223..227
FT                   /note="Histidine box-2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5Q0"
FT   MOTIF           387..391
FT                   /note="Histidine box-3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5Q0"
SQ   SEQUENCE   449 AA;  51467 MW;  E2E33662095855AB CRC64;
     MGGVGEPGGG PGPREGPAPL GAPLPIFRWE QIRQHDLPGD KWLVIERRVY DISRWAQRHP
     GGSRLIGHHS AEDATDAFHA FHQDLHFVRK FLKPLLIGEL APEEPSQDGA QNAQLIEDFR
     ALRQAAEDMK LFEADTTFFA LLLGHILAME LLAWLLVYLL GPGWVSSVLA ALILAISQAQ
     CWCLQHDLGH ASIFPKSRWN HVAQQFVMGQ LKGFSAHWWN FRHFQHHAKP NIFHKDPDVT
     VAPVFLLGES SVEYGKKKRR YLPYNHQHLY FFLIGPPLLT LVNFEVENLA YMLVCMQWTD
     LLWAASFYSR FFLSYSPFYG ATGTLLLFVA VRVLESHWFV WITQMNHIPK EIGHEKHRDW
     ASSQLAATCN VEPSLFIDWF SGHLNFQIEH HLFPTMPRHN YRRVAPLVKA FCAKHGLHYE
     VKPFLTALVD IIGSLKKSGD IWLDAYLHQ
//
